Selecta Biosciences Appoints CMO
This article was originally published in Scrip
Selecta Biosciences Inc., which is developing a novel class of targeted antigen-specific immune therapies using Synthetic Vaccine Particles (SVP), has appointed Dr Earl Sands as chief medical officer. Prior to joining Selecta, Sands was most recently chief medical officer of Targacept.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.